These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 37142191)

  • 1. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models.
    Yi J; Lei X; Guo F; Chen Q; Chen X; Zhao K; Zhu C; Cheng X; Lin J; Yin H; Xia Y
    Antiviral Res; 2023 Jul; 215():105618. PubMed ID: 37142191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
    Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
    mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
    Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
    Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
    Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
    J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration.
    Zeng W; Zheng L; Li Y; Yang J; Mao T; Zhang J; Liu Y; Ning J; Zhang T; Huang H; Chen X; Lu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2284286. PubMed ID: 37982370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
    Yang HC; Chen PJ
    Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Mouse Model Harboring Hepatitis B Virus Covalently Closed Circular DNA.
    Xu Z; Zhao L; Zhong Y; Zhu C; Zhao K; Teng Y; Cheng X; Chen Q; Xia Y
    Cell Mol Gastroenterol Hepatol; 2022; 13(4):1001-1017. PubMed ID: 34896285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication.
    Fei L; Sun S; Yang Q; Huang Y; Li Q; Tao S; Chen L
    Discov Med; 2024 Jun; 36(185):1169-1179. PubMed ID: 38926103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
    Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
    Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
    Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
    Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.
    Zhuang AQ; Chen Y; Chen SM; Liu WC; Li Y; Zhang WJ; Wu YH
    Viruses; 2023 Nov; 15(12):. PubMed ID: 38140556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
    Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
    Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
    Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
    Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo.
    Gorsuch CL; Nemec P; Yu M; Xu S; Han D; Smith J; Lape J; van Buuren N; Ramirez R; Muench RC; Holdorf MM; Feierbach B; Falls G; Holt J; Shoop W; Sevigny E; Karriker F; Brown RV; Joshi A; Goodwin T; Tam YK; Lin PJC; Semple SC; Leatherbury N; Delaney Iv WE; Jantz D; Rhoden Smith A
    Mol Ther; 2022 Sep; 30(9):2909-2922. PubMed ID: 35581938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramolecular recombination enables the formation of hepatitis B virus (HBV) cccDNA in mice after HBV genome transfer using recombinant AAV vectors.
    Ko C; Su J; Festag J; Bester R; Kosinska AD; Protzer U
    Antiviral Res; 2021 Oct; 194():105140. PubMed ID: 34284057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.
    Li H; Sheng C; Wang S; Yang L; Liang Y; Huang Y; Liu H; Li P; Yang C; Yang X; Jia L; Xie J; Wang L; Hao R; Du X; Xu D; Zhou J; Li M; Sun Y; Tong Y; Li Q; Qiu S; Song H
    Front Cell Infect Microbiol; 2017; 7():91. PubMed ID: 28382278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
    Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
    World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced delivery of CRISPR/Cas9 system based on biomimetic nanoparticles for hepatitis B virus therapy.
    Wu K; He M; Mao B; Xing Y; Wei S; Jiang D; Wang S; Alkuhali AA; Guo J; Gan Z; Li M; Li X; Chen H
    J Control Release; 2024 Oct; 374():293-311. PubMed ID: 39151831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonproductive Hepatitis B Virus Covalently Closed Circular DNA Generates HBx-Related Transcripts from the HBx/Enhancer I Region and Acquires Reactivation by Superinfection in Single Cells.
    Peng B; Jing Z; Zhou Z; Sun Y; Guo G; Tan Z; Diao Y; Yao Q; Ping Y; Li X; Ren T; Li B; Li W
    J Virol; 2023 Jan; 97(1):e0171722. PubMed ID: 36475867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide impacts hepatitis B virus core nuclear localization and efficiently interferes with HBV infection.
    Hofmann S; Luther J; Plank V; Oswald A; Mai J; Simons I; Miller J; Falcone V; Hansen-Palmus L; Hengel H; Nassal M; Protzer U; Schreiner S
    Microbiol Spectr; 2024 May; 12(5):e0378823. PubMed ID: 38567974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.